105
Views
10
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLE

Design and structure of the Estonian HIV Cohort Study (E-HIV)

, , , , , , , & show all
Pages 768-775 | Received 17 Dec 2014, Accepted 01 Jun 2015, Published online: 08 Jul 2015
 

Abstract

Background: Estonia is experiencing the new Eastern Europe human immunodeficiency virus (HIV) epidemic, with the highest incidence of new infections in the EU. We describe demographic changes, HIV-related laboratory parameters and co-infections during the concentrated HIV epidemic using the Estonian HIV Cohort Study (E-HIV) database, founded in 2009. Methods: All 3750 subjects in the E-HIV database on December 31, 2013 were included. Subjects were divided into risk groups: people who inject drugs (PWIDs), sexual transmission (heterosexual/homosexual), and other (perinatal) or unknown risk group. Subjects diagnosed before 2009 (first period) and after (second period) were analyzed separately. Results: The mean age at diagnosis has increased from 22.8 years (interquartile range (IQR) = 19.5–27.2) to 29.7 years (IQR = 25.3–36.2) (p < 0.001) between the first and second periods. PWIDs were younger than other transmission groups (23.2 vs 27.1; p < 0.001). There is a statistical difference in the route of transmission among genders, with overall increasing sexual transmission. The most common AIDS-defining illness was tuberculosis (0.5%). HIV/hepatitis C (HCV) co-infection was diagnosed in 42% of cases. The population median CD4 + cell count at diagnosis has declined over the years; in total 53% have been late presenters. Half of the patients are receiving antiretroviral treatment (cART). The most common combinations are nucleoside reverse transcriptase inhibitor (NRTI) backbone plus protease inhibitors (PIs) (57%) or NRTI backbone + non-NRTIs (42%). Conclusion: The E-HIV enables us to fill the gap in the lack of data on the course of the new Eastern European HIV epidemic. These data demonstrate that the HIV epidemic in Estonia is moving from PWIDs to the general population, suggesting that prevention measures and testing guidelines should be revised.

Acknowledgments

The authors are grateful to all personnel helping to enter data into the E-HIV: Merike Karileet, Anne Uus, Irina Sorokina, Merike Meindok, Ljudmilla Ponomarenko, Janika Berning, Marge Vigla, Margarita Sepp, Jelena Vakujeva, Vera Jegorova, Svetlana Semjonova, Anne Junolainen, Tatjana Fishkova, Erika Tiinas, Külli Ottin, Piret Kool, Ülle Valvar. Special thanks to Päivi Pütsepp for critical review of the manuscript.

Declaration of interest: All authors declare no conflicts of interest. E-HIV is financed by the Estonian Ministry of Health and Social Affairs and by the Ministry of Education and Research via Target financing (GARMB 8799, TARMB 2726, SARMB 13122T) and via the Estonian Research Council programme (TerVe). E-HIV is supported by the CASCADE project.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.